MedTrace Logo

Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery

NCT02550145 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2024-12-04

No results posted yet for this study

Summary

The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial glucose reductions after bariatric surgery in a subset of patients who have severe symptomatic hypoglycemia.

Conditions

Interventions

DRUG

Exendin (9-39)

IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).

OTHER

Placebo

IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)

Sponsors & Collaborators

  • Tracey McLaughlin

    lead OTHER

Principal Investigators

  • Colleen Craig, M.D. · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02550145 on ClinicalTrials.gov